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Recombinant human epidermal growth factor (rhEGF)
stimulates the proliferation and migration of epithelial
cells in human cell culture systems and animal models of
partial-thickness skin wounds. This study investigated the
effect of a topical rhEGF ointment on the rate of wound
healing and skin re-epithelialization in a rat full thickness
wound model, and verified whether or not the rhEGF
treatment affected both myofibroblast proliferation and
collagen synthesis in the dermis. When rhEGF (10 µg/g
ointment) was applied topically twice a day for 14 days,
there was significantly enhanced wound closure from the
5th to the 12th day compared with the control (ointment
base treatment) group. A histological examination at the
postoperative 7th day revealed that the rhEGF treatment
increased the number of proliferating nuclear antigen
immunoreactive cells in the epidermis layer. In addition,
the immunoreactive area of alpha-smooth muscle actin
and the expression of prolyl 4-hydroxylase were significantly
higher than those of the control group. Overall, a topical
treatment of rhEGF ointment promotes wound healing by
increasing the rate of epidermal proliferation and accelerating
the level of wound contraction related to myofibroblast
proliferation and collagen deposition.
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Introduction
Wound healing is a complex series of biological events
involving re-epithelialization and granulation that are
mainly mediated by several endogenously released growth
factors such as epidermal growth factor (EGF), fibroblast
growth factor (FGF) and transforming growth factor beta
(TGFβ). Of these growth factors, EGF appears to be the
most important. EGF promotes the proliferation and
differentiation of mesenchymal and epithelial cells.
It has been reported that repeated treatment with EGF
increases the epithelial cell proliferation in a dose dependent
manner and accelerates the wound healing process, whereas
a single EGF treatment has no noticeable effect on the
wound-healing rate [3,12]. There have been many studies
aimed at developing a topical formulation with the sustained
and stable pharmacological properties of recombinant
human EGF (rhEGF) [14,18]. The wound healing properties
of a topical rhEGF treatment have been reported in split- or
partial-thickness skin wound in pigs and guinea pigs,
respectively [2,15]. However, there are almost no reports on
the effect of rhEGF on healing in a full thickness wound
model, which involves both epidermal and dermal impairment.
Therefore, this study investigated whether or not the topical
application of a rhEGF ointment can accelerate the rate of
wound healing, and examined the epidermal and dermal
responses underlying the rhEGF-induced healing effect in a
rat full thickness wound model.
It has been reported that proliferating cell nuclear antigen
(PCNA) expression is closely related to the migration of
keratinocytes and epithelial cells during wound healing
[9,10]. Accordingly, the number of PCNA-positive cells in
the epidermal basal cell layer is a potential marker of an
ongoing re-epithelialization process. On the other hand,
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myofibroblasts are found sporadically at the site of a tissue
injury, and are believed to play a key role in contractile
wound closure [7]. The immunoreactivity of the alpha-smooth
muscle actin protein (α-SMA) in the dermis indicates the
activity of myofibroblasts [16]. Prolyl 4-hydroxylase is an
enzyme residing within the lumen of the endoplasmic reticulum
that plays an important role in the collagen synthesis. This
study investigated the influence of a rhEGF treatment on re-
epithelialization using PCNA immunohistochemistry and
on the modification of myofibroblasts and granulation in the
dermis using α-SMA and prolyl 4-hydroxylase analysis,
respectively.
Materials and Methods
Animals
Male Sprague-Dawley rats, 240-260 g, were obtained
from the laboratory animal center of Seoul National University
(Seoul, Korea). The rats were kept in a colony room with an
ambient temperature of 22
oC and a 12 h light-dark cycle
(7 : 00 AM onset). Food and water were provided ad
libitum. The Animal Care and Use Committee at Seoul
National University approved all of the methods used in this
study.
Recombinant human epidermal growth factor (rhEGF)
The rhEGF was obtained from the biotechnology department
of Daewoong Pharmaceutical Company (Korea). The drug
formulation was prepared by the manufacturer at a dose of
10 µg rhEGF/g of ointment. The ointment base was formulated
with 80% vaseline and 20% liquid paraffin. The rhEGF dose
(10 µg/g) was selected according to the therapeutic guidelines
of the manufacturer and a previous report [5].
The rhEGF treatment in full thickness wound model
The rats were anesthetized using an intraperitoneal
injection of 4% chloral hydrate (1 ml/100 g body weight),
and the dorsal hair of the rat was shaved with clippers, and
disinfected with 70% ethanol and betadine. Two full-
thickness wounds of 2 cm in diameter were marked using a
template and the tissue was excised to the level of the
panniculus carnosus using dissecting scissors and forceps.
The rhEGF ointment (n = 7) or the ointment base (n = 7)
was administered topically to the animals every 12 h for 14
days beginning on the day of the incision. It was reported
that the interaction between rhEGF and its receptor has to be
maintained for 10-12 h in order to achieve an effective
cellular response in terms of better-organized granulation
tissue, a greater DNA and protein content, and a higher rate
of cell proliferation [5]. The animals were housed individually
throughout the experimental period.
Measurement of wound healing
The wound-healing curve and half healing time (HT 50)
were determined by drawing the wound margin daily with
tracing film. The labeled film was scanned, and the wound
area was calculated using image analysis software (Metamorph,
USA). The rate of wound healing is expressed as the
percentage area remaining. The Residual Wound Area (%) =
[R(2~12)/R(1)]×100, where R(1) and R(2~12) denote the remaining
area at postoperative days 1 and 2~12, respectively. The
wound-healing curve was obtained using the Boltzman
equation, and the HT50 value was calculated.
Measurement of PCNA and α-SMA immunoreactive cell
This study was performed in a separated group [rhEGF
treatment group (n = 6) and control (ointment base treatment)
group (n = 6)]. However, all experimental procedures were
same as for the previous wound closure measurements. On
the postoperative 7th day, a 0.5 cm × 2.5 cm skin tissue
sample was harvested from the central regions of the wound,
fixed in 10% neutral formalin, and embedded in paraffin.
Five mm thick sections were cut and mounted on poly-lysin
coated slides. The sections were incubated at 43
oC for 4 h,
deparaffinized in xylene, and hydrated in a graded series of
ethanol. The proliferative cells in the wound area were
identified in four tissue sections per skin sample using a
monoclonal antibody for the proliferating cell nuclear
antigen (PCNA). The deparaffinized section was incubated
with 0.3% hydrogen peroxide in PBS, and preblocked with
1% normal rabbit serum and 0.3% triton X-100 in PBS. The
sections were incubated overnight with the monoclonal
mouse anti-PCNA antibody (1 : 100; Dako, USA) at 4
oC,
and the sections were incubated with biotinylated rabbit
anti-mouse IgG (1 : 200; Vector, USA) for 1 h at room
temperature. After 3 washes, the tissue sections were
processed using the avidin biotin (ABC) method (Vector,
USA), as described elsewhere [11]. Finally, the PCNA
immunoreactive neurons were visualized using a 3,3'-
diamino-benzidine reaction with 0.2% nickel chloride
intensification, which produced black labeled neuronal
nuclei. The myofibroblasts were also evaluated by measuring
the alpha-smooth muscle actin (α-SMA) immunoreactivity
in four tissue sections per sample. The sections were stained
with monoclonal mouse anti α-SMA (1 : 100; Oncogene,
USA) overnight at 4
oC, which was followed by incubation
with Cy3-conjugated anti-mouse IgG (1 : 100; Jackson,
USA) for 1 h at room temperature. Each slide was observed
by optical microscopy with the image being displayed on a
monitor screen via a CCD camera (Micromax Kodak1317;
Princeton, USA) connected to a computer-assisted image
analysis system (Metamorph; Universal Imaging, USA).
The number of PCNA-positive epidermal cells and
immunoreactive areas of the α-SMA positive myofibroblasts
at the epidermal basement membrane zone were measured
in three different areas (300 µm
2 dimension) at both ends as
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Western blot of prolyl 4-hydroxylase
The skin from the post 7day wound was homogenized in a
lysis buffer [50 mM Tris at pH 8.0, 150 mM NaCl, 0.02%
sodium azide, 1% sodium dodecyl sulfate (SDS), 100 µg/ml
phenylmethylsulfonylfluoride (PMSF), 1 µg/ml of aprotinin,
1% igagel 630 (Sigma-Aldrich, USA), and 0.5% deoxycholate]
and centrifuged at 14,000 × g for 30 min at 4
oC. The protein
concentration was determined using a Bradford analysis kit
(Bio-Rad, USA). The total protein was prepared by boiling
the samples for 10 minutes in a SDS sample buffer [50 mM
Tris (pH 6.8), 100 mM DTT, 2% SDS, 0.1% bromophenol
blue, and 10% glycerol]. Equal amounts of the protein were
separated on 12% SDS polyacrylamide gel and transferred
to a nitrocellulose membrane (Hybond ECL; Amersham
Pharmacia, UK). The membrane was blocked for 1 h at
room temperature with a blocking buffer (5% of non-fat
dried milk and 0.1% of BSA in PBS buffer containing 0.1%
Tween 20). The membrane was then incubated for 2 h at
room temperature with 2.5 µg/ml of the anti-prolyl 4-
hydroxylase antibody (Chemicon, USA). After washing
with PBS, the membrane was reincubated with a horseradish
peroxidase labeled secondary antibody and visualized using
a Westzol enhanced chemiluminescence (ECL) detection kit
(Intron, Korea). The bands were detected with LAS-3000
(Fujifilm, Japan). The prolyl 4-hydroxylase bands were
scanned and quantified using the Image J program (v 1.29,
NIH, USA).
Statistical analysis
All values are expressed as the mean ± SE. Statistical
significance in the wound healing time was assessed using
the Bonferroni-test. Unpaired t-tests were used to determine
the probability values between the EGF treated group and
the control group. A value of p< 0.05 was considered significant.
Results
There was no difference between the rhEGF treated and
control (ointment base) groups until the postoperative 4th
day (Fig. 1). However, the rhEGF treated group showed
significantly faster wound healing from the 5th day
compared with the control group and a completely closed
wound on the 12th day (Fig. 1). The half healing time (HT 50)
of the rhEGF treated and control groups were 5.5 ± 0.3 day
and 7.2 ± 0.2 days, respectively.
Quantitative analysis of the PCNA immunoreactivity was
performed to determine the proliferative cell population in
the epithelial margins on the postoperative 7th
 day. The
rhEGF treatment (Fig. 2B and 3A) significantly increased
the number of PCNA positive cells in the basal layer of the
neo-epithelium compared with that of the control group
(Fig. 2A and 3A). The rhEGF treatment significantly increased
the α-SMA immunoreactivity (Fig. 2D and 3B) across the
Fig. 1. The degree of wound healing in the rhEGF (10 µg/g)
treatment group and control (ointment base) group. Residual
wound area (%) = [R(2~12)/R(1)]×100, where R(1) and R(2~12)
represent the area remaining at postoperative days 1 and day
2~12, respectively. The wound-healing curve was fitted using the
Boltzman equation and the half heal time (HT 50). Each bar
represents the mean ± SE. *p < 0.01 compared with the control
(ointment base) group.
Fig. 2. The effect of rhEGF (10 µg/g) on the proliferating cell
nuclear antigen (PCNA) and alpha-smooth muscle actin ( α-
SMA) immunoreactivity in a full-thickness excision wound 7
days after the wound. (A): PCNA immunoreactivity of the
control group, (B): PCNA immunoreactivity of the rhEGF
treated group, (C): α-SMA immunoreactivity of the control
group, (D): α-SMA immunoreactivity of the rhEGF treated
group. The control group was treated with the ointment base. The
arrow indicates PCNA (A and B) or α-SMA (C and D)
immunoreactivity. Scale bar = 200 µm.108 Young-Bae Kwon et al.
dermis, and bundles of filaments appeared in the vessels
compared with that in the control group (Fig. 2C and 3B). In
addition, the rhEGF treatment significantly increased the
prolyl 4-hydroxylase expression level in skin homogenate
on the postoperative 7th day compared with the control
group (Fig. 4).
Discussion
It was reported that the application of various EGF
formulations onto experimentally induced wounds enhances
epithelialization with the concurrent accumulation of
granulation tissue and glycosaminoglycans [4,13,17]. In
particular, the topical application of EGF has been shown to
accelerate the healing rate of open wounds [18]. The present
study also demonstrated that a topical treatment with a
rhEGF ointment significantly reduced the wound closure
time (at least 2 days) in a full thickness wound model
compared with that of the animals treated with the ointment
base only. This indicates that repeated application of rhEGF
has a therapeutic healing effect on various types of traumatic
skin damage.
The epidermal and dermal responses underlying the
rhEGF-ointment-induced rapid wound closure were further
evaluated using histological observations on the postoperative
7th day. Firstly, there was a significant increase in the
number of PCNA immunoreactive cells in the hypertrophic
epithelium after the rhEGF treatment, which demonstrates
that the rhEGF ointment continuously accelerates the
proliferation of epidermal basal cells. There are several
reports showing the accelerative effect of endogenous EGF
or exogeneously treated EGF on re-epithelialization [2,3,5].
Secondly, the rhEGF ointment significantly increased the
α-SMA immunoreactive area (as a marker of myofibroblast)
in the granulation tissue of the wound on the postoperative
7th day. Myofibroblasts appeared in the middle of the
wound healing process, which generated contractile forces
to pull both edges of the open wound until it disappeared via
apoptosis [15]. It was reported that α-SMA is absent 4 days
after wounding but accumulates gradually, beginning from
the 6th day up to the 15th day with a decrease thereafter [6].
These results suggest that the rapid wound closure induced
by the rhEGF treatment was also mediated by the increased
activity of myofibroblasts in the intermediate stages of the
wound healing process.
The rhEGF treatment increased the prolyl 4-hydroxylase
expression level, as a marker of collagen synthesis on the
postoperative 7th day. The increase in collagen synthesis
evokes granulation in the dermis, which helps promote
wound closure. This suggests that the topical application of
Fig. 3. Image analysis data of proliferating cell nuclear antige n
(PCNA) (A) and alpha-smooth muscle actin (α-SMA)
immunoreactivity (B) in a full-thickness excision wound at 7
days. The number of PCNA immunoreactive neuron and the area
of α-SMA expression were significantly increased in the rhEGF
treated group compared with the control (ointment base
treatment) group. *p < 0.01 compared with the control group.
Fig. 4. The effect of the rhEGF (10 µg/g) treatment on the
expression of prolyl 4-hydroxylase (P4H) in a full-thickness
excision wound at 7 days. (A) The expression pattern of P4H,
(B) Density analysis data. The P4H expression level was
markedly increased in the rhEGF treated group compared wit h
the control (ointment base treatment) group. *p < 0.01 compared
with the control group.EGF induces myofibroblast and collagen proliferation 109
a rhEGF ointment accelerates the wound healing process
and the rate of wound contraction by increasing both
epidermal proliferation and dermal granulation.
On the other hand, it is possible that hypertrophic scars
result from excessive collagen deposition at the site of
wound healing, which can be functionally and cosmetically
problematic. To date, TGF-β is known to be the key regulator
of excessive contracture. Recently, it was demonstrated that
rhEGF might negatively regulate the role of TGF-β without
having any influence on scar formation [19]. For example,
topically applied EGF enhances the wound repair process,
whereas it plays a role in decreasing the formation of
excessive scar tissue [8]. In addition, the local application of
EGF modulates the wound tensile strength by decreasing the
histamine level in skin tissue [1]. Because the increase in the
histamine content in a wound area mainly causes epithelial
outgrowth and abnormal collagen formation, a topical EGF
treatment can have a beneficial effect on the wound healing
process without immoderate scar formation. Overall, it is
possible that rhEGF accelerates the natural wound-healing
rate, and simultaneously suppresses the formation of scars. 
In conclusion, the topical application of rhEGF ointment
can induce rapid wound healing by accelerating the
proliferation of new epithelial cells and modulating wound
contraction via myofibroblast proliferation and collagen
deposition in a rat full thickness skin wound model.
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